8-K: Picard Medical Faces NYSE Delisting, Reports Q1 2026 Results

Picard Medical announced first quarter 2026 financial results, including positive gross profit and revenue growth, while also addressing notices from NYSE American regarding continued listing standards and a plan to regain compliance.

Summary

• Picard Medical reported first quarter 2026 revenue of $1.2 million, an 85% increase year-over-year, driven by higher utilization of the SynCardia Total Artificial Heart.
• Gross profit turned positive at $0.3 million with a 24% margin, a significant improvement from a $0.4 million gross loss in Q1 2025.
• The company repaid approximately $7.4 million of a senior secured note and settled an additional $2.1 million through stock issuance.
• Picard Medical received notices from NYSE American for failing to meet continued listing standards related to stockholders' equity and net losses.
• The company has until June 7, 2026, to submit a plan to regain compliance by November 8, 2027.
• A public offering in May 2026 raised $5.0 million in gross proceeds.
• Development of the Emperor Total Artificial Heart is ongoing, targeting a 2028 clinical study launch.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant risk of delisting from NYSE American, despite positive operational progress like revenue growth and positive gross profit. The financial precariousness and ongoing net losses outweigh the short-term operational gains.

Positives

• Revenue grew 85% to $1.2 million in Q1 2026 compared to $0.6 million in Q1 2025.
• Gross profit turned positive at $0.3 million, with a gross margin of 24%, compared to a gross loss of $0.4 million in Q1 2025.
• Significant debt reduction was achieved, with approximately $7.4 million of a senior secured note repaid in cash and $2.1 million settled via equity.
• A public offering in May 2026 successfully raised $5.0 million in gross proceeds.
• The warrant liability decreased from $7.8 million to $4.7 million.
• The remaining Senior Secured Note balance was substantially reduced to approximately $1.3 million.

Negatives

• The company reported a net loss of $7.6 million for Q1 2026, including non-cash charges.
• Picard Medical received two notices from NYSE American for failing to meet continued listing standards.
• As of March 31, 2026, the company reported a stockholders' deficit of approximately $(1.4) million.
• The company has incurred losses from continuing operations and/or net losses in its three most recent fiscal years.

Risks

• Failure to submit an acceptable plan to NYSE American by June 7, 2026, could lead to delisting procedures.
• If compliance with listing standards is not achieved by November 8, 2027, delisting procedures will commence.
• The company's ability to continue as a going concern may be impacted by its financial condition and ongoing losses.
• The .BC indicator appended to the trading symbol may negatively affect investor perception and stock liquidity.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ.

Future Outlook

The Company remains focused on expanding utilization of the SynCardia Total Artificial Heart, advancing development of the Emperor Total Artificial Heart targeting a 2028 clinical study launch, improving manufacturing efficiency, and strengthening its commercial and financial position.

Management Comments

• "We continue to make progress across both our commercial and strategic priorities."
• "During and the quarter, we improved gross margin performance, reduced outstanding debt obligations, strengthened our capital structure, and continued advancing development of the Emperor Total Artificial Heart alongside expansion of our SynCardia commercial activities."
• "The quarter was highlighted by year-over-year revenue growth, a return to positive gross profit, and strengthening the Company's balance sheet through significant debt reduction, while the Company continued to invest in research and development, manufacturing, and clinical support initiatives across its Total Artificial Heart platform."

Industry Context

StockSavvy.ai notes that Picard Medical's situation highlights the challenges faced by medical device companies, particularly those with innovative but capital-intensive technologies, in managing financial stability while pursuing product development and market expansion. The dual focus on commercializing existing products and developing next-generation devices is common, but requires careful financial stewardship to avoid listing standard issues.

Related Party Transactions

• Repaid approximately $0.9 million of related-party debt during the quarter.

Stakeholder Impact

• Shareholders: Potential for delisting from NYSE American, which could negatively impact stock liquidity and valuation. Equity issuance to settle debt dilutes existing shareholders.
• Creditors: The company is actively reducing its debt obligations, including a senior secured note, which is positive for creditors.
• Employees: Continued investment in R&D and operations suggests ongoing employment, but delisting risk could create uncertainty.
• Customers: Continued focus on commercial activity and clinical support for the SynCardia Total Artificial Heart aims to maintain patient access.

Next Steps

• Submit a compliance plan to NYSE American by June 7, 2026.
• Regain compliance with NYSE American continued listing standards by November 8, 2027.
• Continue advancing development of the Emperor Total Artificial Heart, targeting a 2028 clinical study launch.
• Expand utilization of the SynCardia Total Artificial Heart and patient access at transplant centers.
• Improve manufacturing efficiency.
• Strengthen the Company's commercial and financial position.

Key Dates

Recommendation

The company shows positive operational momentum with significant revenue growth and a return to positive gross profit. However, the immediate threat of delisting from NYSE American due to persistent net losses and low stockholders' equity presents a substantial risk. While a capital raise and debt reduction efforts are underway, the path to sustained profitability and compliance remains uncertain. A 'hold' recommendation reflects the balance between operational improvements and significant financial and listing risks.

Keywords

Picard Medical, SynCardia, Total Artificial Heart, NYSE American, Listing Standards, Financial Results, Q1 2026, Debt Reduction